Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Basal Insulin, GLP-1RA, Other Oct 28 | 2022Vertex and Sanofi Q3 ’22 Earnings Updates; Sciwind Reports Positive Interim Results from Ph2b Ecnoglutide Obesity TrialPurchase Blast
$599
Posted in: Glucose Monitoring, Other Oct 27 | 2022Dexcom Q3 ’22 Earnings Update; Kerendia Receives New Recommendations from ADA and KDIGOPurchase Blast
$599
Posted in: Other Oct 27 | 2022Teladoc, Alnylam, and Amarin Q3 ’22 Earnings UpdatesPurchase Blast
$599
Posted in: Insulin Delivery, Other Oct 26 | 2022Biocorp and Novo Sign New Connected Care Agreement; Daprodustat Adcom: 13-3 in Favor of Dapro in DD; 5-11 Against Dapro in NDDPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other Oct 25 | 2022Novartis and Adocia Q3 ’22 Earnings UpdatesPurchase Blast
$599
Posted in: Bolus Insulin, Other Oct 21 | 2022Biocon Receives Second Bs-aspart CRL; EMA Approves Malaysian FacilityPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other Oct 20 | 2022Abbott Q3 ’22 Earnings Update; EMA Expects Ozempic Supply Shortage Into 2023Purchase Blast
$599
Posted in: Insulin Delivery, Other, SGLT2i Oct 18 | 2022Medtronic Launches 770G Personalized Insights Program; GSK Initiates Ph2b NASH Trial; J&J Q3 ’22 Earnings UpdatePurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, Other Oct 17 | 2022Insulet to Replace Omnipod DASH PDMs; Pfizer Initiates New Ph2 QD Oral GLP-1RA vs. Rybelsus Trial; Novartis to Lay Off 400 Employees in DublinPurchase Blast
$599
Posted in: Glucose Monitoring, Other Oct 12 | 2022Sarissa Capital Challenges Amarin’s Management; Nemaura Receives Provisional Purchase Order from TPMENAPurchase Blast
$599
Posted in: Glucose Monitoring, Other Oct 11 | 2022Roche Diabetes Partners with New Mark Cuban CompanyPurchase Blast
$599
Posted in: Bolus Insulin, Other Oct 11 | 2022Lilly Partners with Nimbus Therapeutics for Metabolic Drug Discovery; Arecor Reports Positive Topline Results from Second Ph1 uRAI TrialPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring Oct 10 | 2022Indigo Expands Multi-Metabolite Sensor Development; GlucoTrack to Develop CGM for T1DM; AZ Initiates New Dapa + Zibotentan Ph2 Trial; Sciwind Initiates Patient Dosing in Ph1 Oral GLP-1RA Trial; Ascensia Completes Initial European E3 CGM Launch; October CHMP AgendaPurchase Blast
$599
Posted in: GLP-1RA + Basal, Glucose Monitoring, Other Oct 07 | 2022Abbott Expands Libre 3 Distribution to Pharmacy; Second Ph3 Cagrisema Trial Posted on CT.gov; Galectin NASH Trial to Continue After Second DSMB MeetingPurchase Blast
$599
Posted in: Dual/triple agonist, Other Oct 06 | 2022Tirzepatide Receives Fast Track Designation in Obesity; Provention Bio and Sanofi Join Forces for Potential Teplizumab US LaunchPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other Oct 04 | 2022Dexcom Expands ex-US G7 Launch; Novo to Initiate OASIS 4 Ph3 Oral Sema Obesity Trial; Lilly to Initiate two Lp(a) Ph2 Trials; Better Therapeutic Publishes BT-001 Pivotal Trial Results in Diabetes CarePurchase Blast
$599
Posted in: Basal Insulin Oct 03 | 2022Novo’s QW Insulin Icodec Meets Primary Endpoint in ONWARDS 5Purchase Blast
$599
Posted in: Other Sep 30 | 2022Novo Nordisk and Ventus Therapeutics Partner for NASH; Intercept’s OCA Misses Primary Endpoint in Ph3 REVERSE Trial; Beta Bionics Publishes Pivotal Trial Results in NEJM; Diamyd Completes Dosing Patients in DIAGNODE-B Booster TrialPurchase Blast
$599
Posted in: Other Sep 28 | 2022Dexcom Invests in Nutromics $14M Series B; Vertex and MaxCyte Partnership for CRISPR/Cas9-based Gene-editing ProgramPurchase Blast
$599
Posted in: Dual/triple agonist, Glucose Monitoring, Other Sep 27 | 2022Tirzepatide Approved in Japan; Nemaura and EVERSANA Partner for BEATdiabetes; SURMOUNT-MMO Trial Record PostedPurchase Blast